Related Experiment Videos
Antiangiogenesis for rheumatoid arthritis
Aldo M Roccaro1, Francesca Russo, Teresa Cirulli
1Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, I-70124 Bari, Italy.
Current Drug Targets. Inflammation and Allergy
|February 22, 2005
Summary
New blood vessel formation (angiogenesis) fuels rheumatoid arthritis (RA) pannus. Inhibiting angiogenesis may treat RA by starving and regressing these vessels, offering a potential therapeutic strategy.
Area of Science:
- Rheumatology
- Vascular Biology
- Pathophysiology of Arthritis
Background:
- Rheumatoid arthritis (RA) involves destructive synovitis leading to cartilage and bone erosion.
- Angiogenesis, the formation of new blood vessels, is integral to RA pannus development and progression.
- Inflammatory cell infiltration and neovascularization characterize RA synovitis from early stages.
Purpose of the Study:
- To investigate the role of angiogenesis in rheumatoid arthritis pathogenesis.
- To evaluate the therapeutic potential of anti-angiogenesis strategies for RA treatment.
Main Methods:
- Review of existing literature on angiogenesis in RA.
- Analysis of findings from animal models of arthritis demonstrating the effects of angiogenesis inhibition.
Main Results:
- Angiogenesis is a critical component in the formation and sustenance of the RA pannus.
- Inhibition of angiogenesis in animal models of arthritis has shown a reduction in disease severity.
- Disrupting new blood vessels can impede nutrient supply and promote vessel regression.
Conclusions:
- Angiogenesis is central to maintaining synovitis in rheumatoid arthritis.
- Anti-angiogenesis represents a promising therapeutic approach for RA.
- Pharmacological inhibition of angiogenesis may offer a viable treatment strategy for RA, supported by preclinical evidence.